Third Harmonic Bio Approves Liquidation and Dissolution Plan

The latest update is out from Third Harmonic Bio, Inc. ( (THRD) ).

Third Harmonic Bio, Inc. announced the approval of its liquidation and dissolution plan, with an initial distribution to stockholders expected between $5.30 and $5.35 per share in the third quarter of 2025. The company has initiated the sale process of its asset THB335, which has shown promising results in Phase 1 trials for reducing serum tryptase levels, and is preparing for a Phase 2 clinical trial for treating Chronic Spontaneous Urticaria (CSU).

The most recent analyst rating on (THRD) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Third Harmonic Bio, Inc. stock, see the THRD Stock Forecast page.

Spark’s Take on THRD Stock

According to Spark, TipRanks’ AI Analyst, THRD is a Neutral.

Third Harmonic Bio, Inc. has strong financial stability with high equity and low debt, but the lack of revenue and reliance on financing raise sustainability concerns. The technical analysis indicates a strong upward momentum, although overbought conditions suggest caution. The valuation is weak due to a negative P/E ratio and no dividend yield. Additionally, the recent restructuring plan underscores operational challenges and adds uncertainty to the company’s future prospects.

To see Spark’s full report on THRD stock, click here.

More about Third Harmonic Bio, Inc.

Third Harmonic Bio, Inc. is a company focused on advancing medicine for inflammatory diseases, particularly through the development of KIT inhibitors like THB335, which target mast cell-mediated inflammatory conditions.

Average Trading Volume: 577,835

Technical Sentiment Signal: Sell

Current Market Cap: $239.2M

See more insights into THRD stock on TipRanks’ Stock Analysis page.